QUANTUM X LABS INC. quarterly report, Q2 FY2016

SEC filing summary

Entity discrepancy: The request identifies QUANTUM X LABS INC., but the supplied Form 10-Q is for Emerald Medical Applications Corp. This summary reflects the filing text and does not establish that it belongs to the requested company.

Business context and reporting period

Quarterly report for the three and six months ended June 30, 2016; financial statements are unaudited. Emerald develops and markets DermaCompare, a digital skin-imaging and analytics product. It reported no revenue in either 2016 period. The filing reports 19,474,461 shares outstanding at June 30 and 19,505,711 on August 22, 2016.

Key financial metrics

MetricThree months ended June 30, 2016Six months ended June 30, 2016Comparable 2015 period
Revenue$0$0$0
Operating expenses$1,161,218$3,064,086$242,665 and $421,791, respectively
Operating loss$1,161,218$3,064,086$242,665 and $421,791, respectively
Net loss$1,187,974$3,088,204$251,121 and $431,445, respectively
Basic and diluted loss per share$0.06$0.17$1.18 and $2.03, respectively

At June 30, cash was $274,759, other receivables were $8,212, total assets were $300,706, and current and total liabilities were $534,390. Working capital was negative $251,419, versus negative $147,529 at December 31, 2015. Stockholders’ deficit was $233,684. Six-month operating cash outflow was $536,741; financing provided $701,366, and cash increased by $159,310 to $274,759. The filing reports no meaningful gross margin because revenue was zero.

Changes versus the prior comparable period

  • Revenue remained zero, while six-month net loss rose to $3.09 million from $431,445. General and administrative expense increased to $2.77 million from $174,391, which management attributed largely to new-business costs and share-based compensation.
  • Six-month R&D expense was $295,350, up from $247,400; management described the quarterly decrease in R&D as reflecting a more focused program.
  • Cash rose from $115,449 at year-end, supported by $735,913 in borrowings and offset by $34,547 in debt repayments. Operating cash use remained substantial.
  • Convertible debt increased, with $222,377 reported net of discount on the balance sheet; debt discounts and their amortization contributed to reported expenses.

Outlook, risks, and unusual items

  • Management said the company may need up to an additional $1.5 million over the next 12 months to implement its plan and fund operations. No revenue guidance or quantified sales targets were provided.
  • The filing states that cash resources were insufficient for the business plan and that negative working capital and the absence of revenue raise substantial doubt about the company’s ability to continue as a going concern. Management said it was pursuing additional equity financing.
  • During the six months, the company recorded $2.07 million of shares issued for services and $455,032 of options issued for services in its cash-flow reconciliation. These non-cash items materially affected reported expenses and equity.
  • Outstanding contingent royalties to the Israeli Office of the Chief Scientist were $186,335, plus $15,795 accrued interest, payable on qualifying product sales.
  • A July 7, 2016 subsequent financing involved a $100,000 secured convertible note bearing 8% interest, maturing June 19, 2017, and 250,000 Class A and 250,000 Class B warrants.
  • Management concluded internal control over financial reporting was ineffective, citing the ability of one individual to override controls and accounting software that did not ensure a reliable audit trail or prevent changes to prior periods.
  • The filing contains inconsistent debt descriptions: the balance sheet lists $186,336 of short-term notes, $29,719 of defaulted convertible notes, and $222,377 of convertible notes net of discount, while MD&A gives conflicting classifications and amounts. It also contains a discrepancy in the stated value of shares issued for services in May. The clear values should be verified against the underlying statements and notes.

Important facts for investors to verify

  • Whether this Emerald Medical Applications Corp. filing is actually the filing intended by the request for QUANTUM X LABS INC.
  • The correct classification and carrying amounts of short-term and convertible debt, including the convertible-note discounts, maturity terms, and any defaults.
  • The nature and valuation of share-based compensation and service-provider share issuances, given their material effect on expenses and reported equity.
  • Available financing, cash runway, and progress toward revenue, in light of the going-concern warning and stated need for additional capital.
  • The terms and subsequent accounting for the July 2016 Firstfire note and warrants, as well as the contingent royalty obligation.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.